Oral Cancer News – Page 194

Cancer clip on tobacco pouch

Source: www.telegraphindia.com Author: staff Packets of chewing tobacco sold across India after December 1, 2011 will have to show graphic images portraying the disfiguring effects of oral cancer, but cigarette and bidi packets may show milder pictures, the Union health ministry said today. The health ministry has notified two new sets of pictorial warnings — harsher images for packets of chewing tobacco — that will replace the existing pictures, scorpions on chewed tobacco products, and diseased lungs on cigarette and bidi packets. Cancer and public health specialists have welcomed the new images, but pointed out that the choice of images given to manufacturers of smoking tobacco will allow them to use a milder warning of a man with diseased lungs rather than of mouth cancer. “I’m not happy at all at the choice of pictures for smoking tobacco products,” said Pankaj Chaturvedi, an associate professor of head and neck cancer surgery at the Tata Memorial Hospital, Mumbai. “Pictorial warnings need to have a strong deterrence effect that impacts people — the pictures for chewing tobacco are likely to have such an effect, but the pictures for smoking tobacco don’t,” he said. “The new four pictures for chewing tobacco are very similar and graphically depict the consequences of mouth cancer,” said Monika Arora, the head of health promotion and tobacco control at the Public Health Foundation of India, New Delhi. But three of the four images for smoking tobacco packets show a male with lungs in different stages of disease, while [...]

Oral Cancer Foundation News Team - A2011-05-29T05:51:08-07:00May, 2011|Oral Cancer News|

Philip Morris Int’l purchases license to nicotine system

Source: Associated Press Cigarette maker Philip Morris International Inc. has purchased the rights to a technology that lets users inhale nicotine without smoking. The world's largest nongovernmental cigarette seller told The Associated Press on Thursday it has bought the patent for an aerosol nicotine-delivery system developed by Jed Rose, director of the Center for Nicotine and Smoking Cessation Research at Duke University in Durham, N.C. The school does not have a role in Rose's agreement with the company and won't receive any money. Terms were not disclosed. "By avoiding the burning process altogether, finding a way of giving smokers nicotine to inhale but without those toxic substances that we can reduce the death and disease associated with smoking," said Rose, who led the initial studies in the early 1980s that helped pave the way for commercial nicotine patches as a smoking cessation treatment. "Hopefully it's a wave of the future that inhaling combusted, burning tobacco will someday be a thing of the past." Rose said the next step is for Philip Morris International, with offices in New York and Lausanne, Switzerland, to develop a commercial product using the technology. The system differs from current medicinal nicotine inhalers available on the market as stop-smoking aids because it delivers nicotine more rapidly to mimic the nicotine "hit" a cigarette provides smokers. "The other methods of delivering nicotine fall short of providing smokers with the satisfaction that they crave," Rose said. The move is an "important step in our efforts to develop products [...]

Oral Cancer Foundation News Team - A2011-05-27T10:56:57-07:00May, 2011|Oral Cancer News|

Study findings may change surgical practice

Source: www.digitaljournal.com Author: press release Currently, about 30 per cent of patients who receive oral surgery have their cancer recur. But a new, Canada-wide surgical trial using a new approach to remove tumours and pre-cancerous cells from the mouths of those diagnosed with early-stage oral cancer offers new hope for patients. The Terry Fox Research Institute (TFRI) announces the launch of a $4.7 million Pan-Canadian Phase III clinical trial aimed at improving outcomes for patients undergoing surgery for oral squamous cell cancers. The Canadian Optically Guided Approach for Oral Lesions Surgical Trial (The COOLS Study) has the potential to revolutionize clinical practice here and around the world for this kind of cancer. "Our investment in this promising study is our response to a serious clinical concern expressed by head and neck surgeons across Canada and it has the potential to change surgical practices for cancer of the mouth nationally and internationally," said Dr. Victor Ling, TFRI President and Scientific Director. Using a new surgical approach guided by an existing hand-held light tool, the surgeons, pathologists, and scientists involved in this nine-centre study will determine whether recurrence is reduced when they shift the surgical field for the removal of tumours or pre-cancerous cells in the mouth. The surgeons will use fluorescence visualization (FV) or "blue light" provided by the optical aid rather than traditional white light to determine the tissue to be removed. Under the blue light, normal tissue generates a fluorescence which is absent in tumour or pre-cancerous tissue. The [...]

Oral Cancer Foundation News Team - A2011-05-27T05:26:01-07:00May, 2011|Oral Cancer News|

Blue light tool could save lives of patients suffering from oral cancer

Source: www.google.com/hostednews/canadianpress Author: Camille Bains, The Canadian Press A device that emits a blue light is giving patients undergoing surgery for oral cancer a fighting chance at survival and Canada is at the forefront of research that could have a global impact, researchers say. Doctors and scientists in nine Canadian cities began testing the tool last September as part of a five-year study on 400 patients who are suffering from cancer that has afflicted their tongue or other parts of the mouth. The hand-held fluorescence visualization tool allows surgeons to see cancer cells that can't be detected by conventional white light so they can remove the affected tissue and prevent the disease from recurring. Balvir Dhadda, 47, thought she'd been given a death sentence when she was diagnosed with the deadly disease four years ago after developing a sore underneath the left side of her tongue. "When I got diagnosed, I thought `That's it.'" But Dhadda credits the blue light device for saving her life. "This was the tool used on me, and the rest is history," Dhadda said Thursday. The tool ensured doctors removed only the tissue that was cancerous, rather than the usual practice of removing parts that might potentially be. "I think it was a major factor in the time it took me to recover afterwards," said Dhadda, of Surrey, B.C. Miriam Rosin, the principle investigator of the study, said the blue-light tool developed at the BC Cancer Agency had been used to detect lung, cervical and [...]

Oral Cancer Foundation News Team - A2011-05-27T05:25:36-07:00May, 2011|Oral Cancer News|

Pan-Canadian Surgical Study Offers New Hope for Patients With Early-Stage Oral Cancer

Source: Canada NewsWire VANCOUVER, May 26, 2011 /CNW/ - Currently, about 30 per cent of patients who receive oral surgery have their cancer recur. But a new, Canada-wide surgical trial using a new approach to remove tumours and pre-cancerous cells from the mouths of those diagnosed with early-stage oral cancer offers new hope for patients. The Terry Fox Research Institute (TFRI) announces the launch of a $4.7 million Pan-Canadian Phase III clinical trial aimed at improving outcomes for patients undergoing surgery for oral squamous cell cancers. The Canadian Optically Guided Approach for Oral Lesions Surgical Trial (The COOLS Study) has the potential to revolutionize clinical practice here and around the world for this kind of cancer. "Our investment in this promising study is our response to a serious clinical concern expressed by head and neck surgeons across Canada and it has the potential to change surgical practices for cancer of the mouth nationally and internationally," said Dr. Victor Ling, TFRI President and Scientific Director. Using a new surgical approach guided by an existing hand-held light tool, the surgeons, pathologists, and scientists involved in this nine-centre study will determine whether recurrence is reduced when they shift the surgical field for the removal of tumours or pre-cancerous cells in the mouth. The surgeons will use fluorescence visualization (FV) or "blue light" provided by the optical aid rather than traditional white light to determine the tissue to be removed. Under the blue light, normal tissue generates a fluorescence which is absent in tumour [...]

Oral Cancer Foundation News Team - A2011-05-26T14:56:04-07:00May, 2011|Oral Cancer News|

NHL icon Stan Mikita diagnosed with oral cancer

Source: Huliq.com He is considered by Chicago Blackhawks hockey fans to be one of the greatest hockey players of all time, but he now faces his greatest challenge as it was announced Stan Mikita has cancer. The statement was released by the Blackawks organization today. The statement was that Mikita was diagnosed with stage 1 oral cancer. According to Chicago press reports, Mikita was diagnosed with the condition at Loyola Medical Center in downtown Chicago. The report from the team stated that the diagnosis was of early stage tongue cancer. The statement also said that, since the disease was found early, he stands a good chance of responding to treatment. The release also asked that the press not ask the team for further information about Mikita’s condition. The statement was that it was a personal matter between Mikita and his family and his doctors. No further statements about his condition will be released by the team. Stan Mikita was originally from Canada. He eventually came to the United States and played in the early days of the NHL. They played for the Chicago Blackhawks in the late 1950s and early 1960s. He was on the team when they beat the Detroit Redwings to win the Stanely Cup in 1961. Mikita played professional hockey throughout the 1970s. He finally retired due to chronic back pain in 1980. He has been inducted into the Hockey Hall of Fame. During his time as a player he was the league MVP twice. He is [...]

Oral Cancer Foundation News Team - A2011-05-25T10:41:22-07:00May, 2011|Oral Cancer News|

High risk of developing ONJ for cancer patients on bisphosphonates

Source: Dr.Bicuspid.com Research has shown that cancer patients on bisphosphonates are at risk of developing osteonecrosis of the jaw (ONJ) and that those on the intravenous form of the drug are at a higher risk compared with those on the oral drugs. However, a new study that looked at cancer patients on zoledronic acid (ZOL) and chemotherapy combined with the antiangiogenic agent bevacizumab (BEV) who underwent a dental exam before starting treatment found that none of them developed ONJ (JADA, May 2011, Vol. 142:5, pp. 506-513). Researchers from the University of Siena in Italy investigated the incidence of and risk factors for ONJ in patients with metastases to the bone from solid tumors who received ZOL and BEV. Their study included 59 patients (34 with breast cancer and 25 with non-small cell lung cancer [NSCL]) who received 4 mg of ZOL intravenously every four weeks and 15 mg per kg of BEV every three weeks. The median time the participants received ZOL therapy was 18 months, while the median time participants received BEV therapy was 16 months. The researchers took several measures to reduce the study participants' risk of developing ONJ, including the following: Dental caries and periodontal disease were treated before starting study treatment. Mouth rinses with chlorhexidine and local antibiotic agents were administered before baseline oral hygiene. Recommendations were made for maintaining good oral hygiene. Teeth were extracted at least four weeks before starting ZOL and BEV therapy. Invasive dental procedures were avoided during treatment. If invasive dental [...]

Oral Cancer Foundation News Team - A2011-05-24T10:21:55-07:00May, 2011|Oral Cancer News|

FDA to regulate cigarette pack labeling

Source: Dr.Bicuspid May 19, 2011 -- Cigarette manufacturers have deceived consumers about the risks of their products for years, and remedial actions are needed so consumers can make informed decisions about the products they purchase, according to researchers from the Roswell Park Cancer Institute (RPCI). The researchers evaluated the messages that cigarette pack labels convey to smokers and nonsmokers, and their findings will be published in three studies in an upcoming issue of the American Journal of Preventive Medicine (June 2011, Vol. 40:6, pp. 674-698). "Tobacco companies have used attractive packaging and persuasive images to market their products for decades," said lead author Maansi Bansal-Travers, PhD, a behavioral research scientist at RPCI, in a press release. "These studies support efforts by the [U.S. Food and Drug Administration] to regulate cigarette pack labeling." Tobacco manufacturers have effectively used cigarette pack design, colors, and descriptive terms to create the illusion that filtered and so-called light/mild cigarettes are safer than unfiltered and full-flavor cigarettes, when this is not the case. Beginning in June 2010, regulations contained in the Family Smoking Prevention and Tobacco Control Act have prohibited tobacco companies from using descriptive terms such as "light," "mild," or "low" in advertising and on cigarette packaging. "While the removal of these obviously misleading terms was a good first step, we discovered that cigarette manufacturers have circumvented the regulation by using different terms such as 'gold' and 'silver' and changing the colors on packs to continue to mislead consumers about their products," Bansal-Travers said. The [...]

Oral Cancer Foundation News Team - A2011-05-24T10:10:32-07:00May, 2011|Oral Cancer News|

Touched by another human’s touch

Source: www.latimes.com Author: Itzhak Brook, M.D. I was deeply shaken to learn I had hypopharyngeal cancer. As a physician, I had access to my hospital's laboratory results, so I took a shortcut: Rather than wait for my surgeon to call me, I looked for my name in my hospital's pathology laboratory log book. After my name, the log book stated in no uncertain terms: "mildly differentiated squamous cell carcinoma." I could not believe my eyes. Was this possible? Could it be a mistake? In spite of the hopeful questions that permeated my mind, I knew it was not a mistake: Right here, in front of me, in black and white — my own death sentence. Still, to be convinced that the diagnosis was real, I had to view the biopsy specimens under the microscope myself — and there it was. In that very instant, my whole world changed. I had always had a sense of invulnerability. Now I was left with uncertainty about my prognosis and future. I was in a state of desperation and disbelief when I left the pathology laboratory and walked into my internist's office to break the news to him. He slowly got out of his chair without uttering a word and gave me a big, supportive hug. It felt so good to know that he deeply cared for me beyond our professional relationship. His embrace moved me — made me feel that I was surrounded by those who truly appreciated my pain and distress, and [...]

Oral Cancer Foundation News Team - A2011-05-24T06:39:31-07:00May, 2011|Oral Cancer News|

Boys and HPV Vaccine: The Facts

Source: Forbes Magazine CNN reports on a study that argues that boys should get vaccinated for the human papilloma virus (HPV), which causes cervical cancer in women. But it misses the main reason that boys should be getting jabs of either Merck‘s Gardasil or GlaxoSmithKline’s rival Cervarix. Cue CNN: Men also carry the human papillomavirus, the virus that can lead to male cancers and genital warts. And they could spread HPV to their sexual partners, putting those people at risk for cervical cancer. So the HPV vaccine, that is often recommended for girls, should extend to boys as well, say researchers from Innsbruck Medical University in Austria. Their study was presented at the meeting of the American Urological Association on Tuesday. …. In the study, Dr. Michael Ladurner Rennau and his colleagues tested 133 men, between 7 months to 82 years old for the presence of HPV, one of the most common sexually transmitted infections. They used DNA extraction. They found 18.8% of the examined foreskins had the low-risk HPV genotypes and 9.77% had the high-risk HPV. via Males should get HPV vaccine too, study says – The Chart – CNN.com Blogs. Of course, the reason there’s not a big push to vaccinate men for HPV is because genital warts are treatable and penile and anal cancers are rare. And saying, “Let’s vaccinate your son so that the women he sleeps with won’t get HPV” is an uncomfortable and probably unconvincing approach for pediatricians to take with parents. Girls — [...]

Oral Cancer Foundation News Team - A2011-05-23T12:25:32-07:00May, 2011|Oral Cancer News|